Back to Dashboard

75276617ALE1001

AML-MDS•NCT07295951•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

Bleximenib

Mechanism of Action

Menin-KMT2A (MLL1) inhibitor

Sponsor

Unknown

Design

II

Control Arm

-

Criteria

Inclusion Criteria

Cohort A1: KMT2A-r AML Cohort A2: NPM1m AML

Age: ≥18 years Phase: II

Exclusion Criteria

Enrollment

Progress0 / 2

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620